← Leaderboards

Timothy J Wilkin

Columbia University Health Sciences

Google Scholar ↗PubMed ↗ORCID ↗

$15,325,032

Attributed

$17,236,984

Total exposure

23

Grants

20

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $5.9M · FY2005–25

$10M$7.5M$5M$2.5M$0

'05

'06

'07

'08

'09

'10

'11

'12

'13

'14

'15

'16

'17

'18

'19

'20

'21

'22

'23

'24

'25

Funding mix

By agency

NIH$26,647,290 · 24

By mechanism

U54$16,077,761 · 8

UM1$4,036,960 · 1

M01$2,955,167 · 12

UG1$2,867,928 · 1

K23$653,400 · 1

F32$56,074 · 1

Top collaborators

Most similar at Columbia University Health Sciences

Same institution · by research overlap

Others in their field

Top investigators on “Research Personnel”

David Heimbrook · Leidos Biomedical Research, Inc.$701,463,488
Sonia M Thomas · Research Triangle Institute$700,865,642
Leonard Freedman · Leidos Biomedical Research, Inc.$557,978,666
Tracy L Nolen · Research Triangle Institute$474,487,152
David R. Weir · University Of Michigan At Ann Arbor$364,053,504
Judith S. Currier · University Of California Los Angeles$284,675,012

Research focus

Research PersonnelClinical TrialsHuman Papilloma Virus-Related Malignant NeoplasmHuman PapillomavirusMexicoBrazilPuerto RicoPreventionSiteCervicalWomanCollaborationsLatin AmericaFutureHpv-High RiskMentorsResourcesPreventInstitutionPersonsMalignant Neoplasm Of Cervix UteriCervical Cancer PreventionCervical Cancer ScreeningCaribbean Region

Grant awards (57)

UCSD Collaborative Clinical Trials Unit$3,705,021

UM1 · FY2025 · AI · contact PI

Partnership for advancing cervical cancer prevention in women living with HIV (CASCADE - Research Hub)$772,023

UG1 · FY2025 · CA · contact PI

Partnership for Prevention of HPV-Associated Cancers in People Living with HIV: Brazil, Mexico, and Puerto Rico - Supplemental Extension$401,386

U54 · FY2025 · CA

Partnership for Prevention of HPV-Associated Cancers in People Living with HIV: Brazil, Mexico, and Puerto Rico$372,895

U54 · FY2025 · CA

UCSD Collaborative Clinical Trials Unit$331,939

UM1 · FY2025 · AI · contact PI

Partnership for Prevention of HPV-Associated Cancers in People Living with HIV: Brazil, Mexico, and Puerto Rico$275,720

U54 · FY2025 · CA

Partnership for Prevention of HPV-Associated Cancers in People Living with HIV: Brazil, Mexico, and Puerto Rico$1,692,850

U54 · FY2024 · CA

Partnership for advancing cervical cancer prevention in women living with HIV (CASCADE - Research Hub)$679,304

UG1 · FY2024 · CA · contact PI

Partnership for advancing cervical cancer prevention in women living with HIV (CASCADE - Research Hub)$64,328

UG1 · FY2024 · CA · contact PI

Partnership for Prevention of HPV-Associated Cancers in People Living with HIV: Brazil, Mexico, and Puerto Rico$1,553,664

U54 · FY2023 · CA

Clinical Trials Program$954,399

U54 · FY2023 · CA · contact PI

Partnership for advancing cervical cancer prevention in women living with HIV (CASCADE - Research Hub)$650,074

UG1 · FY2023 · CA · contact PI

Administrative and Coordinating Core$294,153

U54 · FY2023 · CA · contact PI

Data Management & Statistical Core$198,401

U54 · FY2023 · CA · contact PI

Central Laboratory Core$106,711

U54 · FY2023 · CA · contact PI

Partnership for advancing cervical cancer prevention in women living with HIV (CASCADE - Research Hub)$702,199

UG1 · FY2022 · CA · contact PI

Administrative and Coordinating Core$1

U54 · FY2022 · CA · contact PI

Partnership for Prevention of HPV-Associated Cancers in People Living with HIV: Brazil, Mexico, and Puerto Rico$1

U54 · FY2022 · CA · contact PI

Partnership for Prevention of HPV-Associated Cancers in People Living with HIV: Brazil, Mexico, and Puerto Rico$1,651,550

U54 · FY2021 · CA · contact PI

Clinical Trials Program$1,013,863

U54 · FY2021 · CA · contact PI

Administrative and Coordinating Core$307,153

U54 · FY2021 · CA · contact PI

Data Management & Statistical Core$213,029

U54 · FY2021 · CA · contact PI

Central Laboratory Core$117,505

U54 · FY2021 · CA · contact PI

Partnership for Prevention of HPV-Associated Cancers in People Living with HIV: Brazil, Mexico, and Puerto Rico$1,660,379

U54 · FY2020 · CA · contact PI

Clinical Trials Program$1,017,165

U54 · FY2020 · CA · contact PI

Administrative and Coordinating Core$315,777

U54 · FY2020 · CA · contact PI

Data Management & Statistical Core$213,029

U54 · FY2020 · CA · contact PI

Central Laboratory Core$114,408

U54 · FY2020 · CA · contact PI

Partnership for Prevention of HPV-Associated Cancers in People Living with HIV: Brazil, Mexico, and Puerto Rico$1,801,861

U54 · FY2019 · CA · contact PI

Clinical Trials Program$1,089,913

U54 · FY2019 · CA · contact PI

Administrative and Coordinating Core$349,762

U54 · FY2019 · CA · contact PI

Data Management & Statistical Core$230,404

U54 · FY2019 · CA · contact PI

Central Laboratory Core$131,782

U54 · FY2019 · CA · contact PI

ANAL DYSPLASIA AND ANAL HPV IN HIV-POSITIVE AND HIV-NEGATIVE MEN$86,070

M01 · FY2007 · RR · contact PI

A5197: A PHASE II DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE$4,213

M01 · FY2007 · RR · contact PI

DIM STUDY$3,160

M01 · FY2007 · RR · contact PI

A5146: A PHRASE II RANDOMIZED CONTROLLED TRIAL EVALUATING THE IMPACT OF THERAPEU$530

M01 · FY2007 · RR · contact PI

A5201: A PROSPECTIVE, OPEN-LABEL, PILOT TRIAL OF REGIMEN SIMPLIFICATION TO ATAZA$263

M01 · FY2007 · RR · contact PI

ANAL DYSPLASIA AND ANAL HPV IN HIV-POSITIVE AND HIV-NEGATIVE MEN$702,641

M01 · FY2006 · RR · contact PI

Anal Dysplasia in HIV+ and HIV- men$130,680

K23 · FY2006 · AI · contact PI

A5146: A PHRASE II RANDOMIZED CONTROLLED TRIAL EVALUATING THE IMPACT OF THERAPEU$82,516

M01 · FY2006 · RR · contact PI

A5201: A PROSPECTIVE, OPEN-LABEL, PILOT TRIAL OF REGIMEN SIMPLIFICATION TO ATAZA$77,513

M01 · FY2006 · RR · contact PI

A5197: A PHASE II DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE$7,501

M01 · FY2006 · RR · contact PI

A5170: PREDICTORS OF IMMUNOLOGIC AND CLINICAL PROGRESSION IN SUBJECTS W/ CD4+$5,003

M01 · FY2006 · RR · contact PI

ANAL DYSPLASIA AND ANAL HPV IN HIV-POSITIVE AND HIV-NEGATIVE MEN$546,331

M01 · FY2005 · RR

A5146: A PHRASE II RANDOMIZED CONTROLLED TRIAL EVALUATING THE IMPACT OF THERAPEU$134,120

M01 · FY2005 · RR

Anal Dysplasia in HIV+ and HIV- men$130,680

K23 · FY2005 · AI

A5170: PREDICTORS OF IMMUNOLOGIC AND CLINICAL PROGRESSION IN SUBJECTS W/ CD4+$74,950

M01 · FY2005 · RR

A5197: A PHASE II DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUAT$29,585

M01 · FY2005 · RR

A5201: A PROSPECTIVE, OPEN-LABEL, PILOT TRIAL OF REGIMEN SIMPLIFICATION TO ATAZA$7,887

M01 · FY2005 · RR

ANAL DYSPLASIA AND ANAL HPV IN HIV-POSITIVE AND HIV-NEGATIVE MEN$935,685

M01 · FY2004 · RR

A5170: PREDICTORS OF IMMUNOLOGIC AND CLINICAL PROGRESSION IN SUBJECTS W/ CD4+>$257,199

M01 · FY2004 · RR

Anal Dysplasia in HIV+ and HIV- men$130,680

K23 · FY2004 · AI

Anal Dysplasia in HIV+ and HIV- men$130,680

K23 · FY2003 · AI

Anal Dysplasia in HIV+ and HIV- men$130,680

K23 · FY2002 · AI

A study to screen HIV+ men for ASIL and anal HPV$10,514

F32 · FY2002 · CA

A study to screen HIV+ men for ASIL and anal HPV$45,560

F32 · FY2001 · CA